Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

308.07 -2.73 (-0.88%)
Official Closing Price Updated: 4:15 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 757,291
Open 308.37
Bid (Size) 307.55 (1)
Ask (Size) 307.85 (9)
Prev. Close 310.80
Today's Range 301.97 - 310.09
52wk Range 263.56 - 417.81
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Examining the Quality Attributes of UNITED THERAPEUTICS CORP (NASDAQ:UTHR).
A fundamental analysis of (NASDAQ:UTHR): Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) qualifies as a quality stock. 
Via Chartmill
3 Big Reasons to Love United Therapeutics (UTHR)
What a brutal six months it’s been for United Therapeutics. The stock has dropped 23.1% and now trades at $308, rattling many shareholders. This might have investors contemplating their next move. 
Via StockStory

Performance

YTD
-14.5%
-14.5%
1 Month
+8.4%
+8.4%
3 Month
-12.8%
-12.8%
6 Month
-23.1%
-23.1%
1 Year
+16.5%
+16.5%

More News

Read More
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Following Peter Lynch’s approach: Does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fit the bill?
Via Chartmill
Earnings Scheduled For April 30, 2025
Via Benzinga
The Top 3 Stock Picks at the World’s Greatest Hedge Fund
Via MarketBeat
Topics Regulatory Compliance
Exposures Legal Regulatory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity
Via Chartmill
1 Value Stock Worth Investigating and 2 to Brush Off
Via StockStory
United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1
Via StockStory
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Government World Trade
Exposures Political Tariff
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Via Benzinga
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Via Benzinga
Demystifying United Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
From United Therapeutics Corporation
Via Business Wire
How does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) stack up against Peter Lynch’s investment principles?
Via Chartmill
2 of Wall Street’s Favorite Stocks to Target This Week and 1 to Question
Via StockStory
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Quality Investors May Find UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Attractive.
Via Chartmill
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
From United Therapeutics Corporation
Via Business Wire
3 Reasons Investors Watch United Therapeutics (UTHR)
Via StockStory
Topics Stocks
Exposures US Equities
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 308.07
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 05/13/25 04:15 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 13.83B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.